PureTech Health (PRTC) 2019年年度报告「LSE」.pdf

1、PureTech Health plc Annual report and accounts 2019PureTech Health plc Annual report and accounts 2019D E V E L O P I N GM E D I C I N E S1 Unless the context specifically indicates otherwise,references in this report to“Founded Entities”refer to the entities that PureTech founded and in which PureT

2、ech continues to hold equity.While PureTech maintains ownership of equity interests in its Founded Entities,the Company does not,in all cases,maintain control over these entities(by virtue of(i)majority voting control and(ii)the right to elect representation to the entities board of directors)or dir

3、ect the management and development efforts for these entities.Consequently,not all such entities are consolidated in the financial statements.Where PureTech maintains control,the entity is referred to as aControlled Founded Entity in this report and is consolidated in the financial statements.Where

4、PureTech does not maintain control,the entity is referred to as aNon-Controlled Founded Entity in this report and is not consolidated in the financial statements.As of 31 December 2019,Controlled Founded Entities include Alivio Therapeutics,Inc.,Follica,Incorporated,Entrega,Inc.,Vedanta Biosciences,

5、Inc.and Sonde Health,Inc.,and Non-Controlled Founded Entities include Akili Interactive Labs,Inc.,Gelesis,Inc.,Karuna Therapeutics,Inc.,Vor Biopharma Inc.and,for all periods prior to December 18,2019,resTORbio,Inc.2 PureTech Level Pro-forma Cash Reserves is an alternative performance measure(APM)whi

6、ch includes the PureTech Level Cash Reserves of$120.6 million and the$200.9 million in proceeds from the 22 January 2020 sale of 2.1 million Karuna common shares.PureTech Level Cash Reserves represent cash balances and short-term investments held at PureTech Health LLC,PureTech Management,Inc.,PureT